The results show that switching from an aromatase inhibitor to camizestrant in combination with any of the three CDK4/6 inhibitors … delays progression of disease and extends the benefit of 1st-line ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market ... in combination with CDK4/6 inhibitor drugs – such as Pfizer's Ibrance ...

However, given the recent failure of Sanofi's oral SERD amcenestrant in the phase 2 AMEERA-3 trial – which included a similar patient population – the new result is a worrying readout for the ...

Considering taking supplements to treat aromatase inhibitor induced arthralgia? Below is a list of common natural remedies used to treat or reduce the symptoms of aromatase inhibitor induced ...

Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its ligand, programmed cell ...

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader (SERD), in patients with ...

Off-label uses outside of the drug's formal Food and Drug Administration (FDA) approval can include migraines and other health issues. Researchers continue to investigate ACE inhibitor use in treating ...